Volume 29, Number 11—November 2023
Research Letter
Tuberculosis Variant with Rifampin Resistance Undetectable by Xpert MTB/RIF, Botswana
Figure
![Timeline of events experienced by case-patient in Botswana from study of a rifampin-resistant TB variant not detectable using Xpert MTB/RIF assay (Cepheid, https://www.cepheid.com). Timeline events included routine laboratory procedures, study procedures, and timing of TB treatment. 2HRZ(E)/4HR, standard 6-month tuberculosis treatment regimen (2 months of isoniazid, rifampin and pyrazinamide, with or without ethambutol, followed by 4 months of isoniazid and rifampin); DST, drug susceptibility testing; EMB, ethambutol; INH, isoniazid; LFX, levofloxacin; MDR TB, multidrug-resistant tuberculosis; MFX, moxifloxacin; PZA, pyrazinamide; RMP, rifampin; SM, streptomycin; TB, tuberculosis; WGS, whole-genome sequencing; Xpert, GeneXpert.](/eid/images/23-0987-F1.jpg)
Figure. Timeline of events experienced by case-patient in Botswana from study of a rifampin-resistant TB variant not detectable using Xpert MTB/RIF assay (Cepheid, https://www.cepheid.com). Timeline events included routine laboratory procedures, study procedures, and timing of TB treatment. 2HRZ(E)/4HR, standard 6-month tuberculosis treatment regimen (2 months of isoniazid, rifampin and pyrazinamide, with or without ethambutol, followed by 4 months of isoniazid and rifampin); DST, drug susceptibility testing; EMB, ethambutol; INH, isoniazid; LFX, levofloxacin; MDR TB, multidrug-resistant tuberculosis; MFX, moxifloxacin; PZA, pyrazinamide; RMP, rifampin; SM, streptomycin; TB, tuberculosis; WGS, whole-genome sequencing; Xpert, GeneXpert.
Page created: September 28, 2023
Page updated: October 23, 2023
Page reviewed: October 23, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.